Stereotactic Body Radiotherapy (SBRT) of Pancreatic Cancer-A
Critical Review and Practical Consideration

J 2022

Stereotactic Body Radiotherapy (SBRT) of Pancreatic Cancer-A Critical Review and Practical Consideration

BURKOŇ, Petr, Jan TRNA, Marek SLÁVIK, Radim NĚMEČEK, Tomáš KAZDA et. al.

Basic information

Original name

Stereotactic Body Radiotherapy (SBRT) of Pancreatic Cancer-A Critical Review and Practical Consideration

Authors

BURKOŇ, Petr (203 Czech Republic, belonging to the institution), Jan TRNA (203 Czech Republic, guarantor, belonging to the institution), Marek SLÁVIK (703 Slovakia, belonging to the institution), Radim NĚMEČEK (203 Czech Republic, belonging to the institution), Tomáš KAZDA (203 Czech Republic, belonging to the institution), Petr POSPÍŠIL (203 Czech Republic, belonging to the institution), Milan DASTYCH (203 Czech Republic, belonging to the institution), Michal EID (203 Czech Republic, belonging to the institution), Ivo NOVOTNY (203 Czech Republic), Tomáš PROCHÁZKA (203 Czech Republic, belonging to the institution) and Miroslav VRZAL (203 Czech Republic)

Edition

Biomedicines, Basel, MDPI, 2022, 2227-9059

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 4.700

RIV identification code

RIV/00216224:14110/22:00127201

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.3390/biomedicines10102480

UT WoS

000872249300001

Keywords in English

pancreatic neoplasms; neoadjuvant therapy; stereotactic body radiotherapy; review

Abstract

V originále

Pancreatic cancer is the third leading cause of cancer death in the developed world and is predicted to become the second by 2030. A cure may be achieved only with surgical resection of an early diagnosed disease. Surgery for more advanced disease is challenging and can be contraindicated for many reasons. Neoadjuvant therapy may improve the probability of achieving R0 resection. It consists of systemic treatment followed by radiation therapy applied concurrently or sequentially with cytostatics. A novel approach to irradiation, stereotactic body radiotherapy (SBRT), has the potential to improve treatment results. SBRT can deliver higher doses of radiation to the tumor in only a few treatment fractions. It has attracted significant interest for pancreatic cancer patients, as it is completed quickly, requires less time away from full-dose chemotherapy, and is well-tolerated than conventional radiotherapy. In this review, we aim to provide the reader with a basic overview of current evidence for SBRT indications in the treatment of pancreatic tumors. In the second part of the review, we focus on practical information with respect to SBRT treatment plan preparation the performance of such therapy. Finally, we discuss future directions related to the use of magnetic resonance linear accelerators.

Links

90125, large research infrastructures

Name: BBMRI-CZ III

90128, large research infrastructures

Name: CZECRIN III

Citovat

BURKOŇ, Petr, Jan TRNA, Marek SLÁVIK, Radim NĚMEČEK, Tomáš KAZDA, Petr POSPÍŠIL, Milan DASTYCH, Michal EID, Ivo NOVOTNY, Tomáš PROCHÁZKA and Miroslav VRZAL. Stereotactic Body Radiotherapy (SBRT) of Pancreatic Cancer-A Critical Review and Practical Consideration. Biomedicines. Basel: MDPI, 2022, vol. 10, No 10, p. 1-23. ISSN 2227-9059. Available from: https://dx.doi.org/10.3390/biomedicines10102480.

@article{2233281,
   author = {Burkoň, Petr and Trna, Jan and Slávik, Marek and Němeček, Radim and Kazda, Tomáš and Pospíšil, Petr and Dastych, Milan and Eid, Michal and Novotny, Ivo and Procházka, Tomáš and Vrzal, Miroslav},
   article_location = {Basel},
   article_number = {10},
   doi = {http://dx.doi.org/10.3390/biomedicines10102480},
   keywords = {pancreatic neoplasms; neoadjuvant therapy; stereotactic body radiotherapy; review},
   language = {eng},
   issn = {2227-9059},
   journal = {Biomedicines},
   title = {Stereotactic Body Radiotherapy (SBRT) of Pancreatic Cancer-A Critical Review and Practical Consideration},
   url = {https://www.mdpi.com/2227-9059/10/10/2480},
   volume = {10},
   year = {2022}
}

TY  - JOUR
ID  - 2233281
AU  - Burkoň, Petr - Trna, Jan - Slávik, Marek - Němeček, Radim - Kazda, Tomáš - Pospíšil, Petr - Dastych, Milan - Eid, Michal - Novotny, Ivo - Procházka, Tomáš - Vrzal, Miroslav
PY  - 2022
TI  - Stereotactic Body Radiotherapy (SBRT) of Pancreatic Cancer-A Critical Review and Practical Consideration
JF  - Biomedicines
VL  - 10
IS  - 10
SP  - 1-23
EP  - 1-23
PB  - MDPI
SN  - 22279059
KW  - pancreatic neoplasms
KW  - neoadjuvant therapy
KW  - stereotactic body radiotherapy
KW  - review
UR  - https://www.mdpi.com/2227-9059/10/10/2480
N2  - Pancreatic cancer is the third leading cause of cancer death in the developed world and is predicted to become the second by 2030. A cure may be achieved only with surgical resection of an early diagnosed disease. Surgery for more advanced disease is challenging and can be contraindicated for many reasons. Neoadjuvant therapy may improve the probability of achieving R0 resection. It consists of systemic treatment followed by radiation therapy applied concurrently or sequentially with cytostatics. A novel approach to irradiation, stereotactic body radiotherapy (SBRT), has the potential to improve treatment results. SBRT can deliver higher doses of radiation to the tumor in only a few treatment fractions. It has attracted significant interest for pancreatic cancer patients, as it is completed quickly, requires less time away from full-dose chemotherapy, and is well-tolerated than conventional radiotherapy. In this review, we aim to provide the reader with a basic overview of current evidence for SBRT indications in the treatment of pancreatic tumors. In the second part of the review, we focus on practical information with respect to SBRT treatment plan preparation the performance of such therapy. Finally, we discuss future directions related to the use of magnetic resonance linear accelerators.
ER  -

BURKOŇ, Petr, Jan TRNA, Marek SLÁVIK, Radim NĚMEČEK, Tomáš KAZDA, Petr POSPÍŠIL, Milan DASTYCH, Michal EID, Ivo NOVOTNY, Tomáš PROCHÁZKA and Miroslav VRZAL. Stereotactic Body Radiotherapy (SBRT) of Pancreatic Cancer-A Critical Review and Practical Consideration. \textit{Biomedicines}. Basel: MDPI, 2022, vol.~10, No~10, p.~1-23. ISSN~2227-9059. Available from: https://dx.doi.org/10.3390/biomedicines10102480.

Detailed Information on Publication Record